

Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit

Nanexa AB and VitriVax, Inc. jointly announce that they have resolved the patent infringement lawsuit filed by Nanexa AB against VitriVax, Inc. in the United States District Court for the District of Delaware.

The Amended Complaint in that action has been dismissed on the basis of a confidential Settlement Agreement with a contingent licensing mechanism. As part of the parties' confidential Settlement Agreement, VitriVax has represented and warranted that it is not practicing and has agreed in the future not to practice, the inventions that are claimed in those patents, nor assist any third party in doing the same for the term of those patents.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit](#)